Advances in ex vivo T cell depletion - where do we stand?-Reference-Cited by-同舟云学术

Advances in ex vivo T cell depletion - where do we stand?

Published:2018-12-04 Issue:1 Volume:2 Page:e29
ISSN:2573-8461
Container-title:Advances in Cell and Gene Therapy
language:en
Short-container-title:Adv Cell Gene Ther

Author:

Bryant Adam R.¹^ORCID,Perales Miguel-Angel¹²

Affiliation:

1. Adult Bone Marrow Transplant Service; Department of Medicine; Memorial Sloan Kettering Cancer Center; New York New York

2. Department of Medicine; Weill Cornell Medical College; New York New York

Funder

National Institutes of Health

National Cancer Institute

Ottawa Hospital

Department of Medicine Post Graduate Medical Educational

Ottawa Hospital Research Institute

Publisher

Hindawi Limited

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acg2.29/fullpdf

Reference60 articles.

1. D'Souza AF Fretham C Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017 2017

2. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors;Nash;Blood,2000

3. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells;Inamoto;Biol Blood Marrow Transplant,2011

4. Antilymphocyte globulin for prevention of chronic graft-versus-host disease;Kroger;N Engl J Med,2016

5. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial;Walker;Lancet Oncol,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients;Blood Advances;2024-09-10

2. Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation;Bone Marrow Transplantation;2024-02-13

3. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion;Transplantation and Cellular Therapy;2023-04

4. Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice;Transplantation and Cellular Therapy;2022-08

5. A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease;Stem Cell Reviews and Reports;2020-08-01